Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials
Manson JE, Bassuk SS, Buring JE, VITAL Research Group
The Journal of steroid biochemistry and molecular biology · 116 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- National Cancer Institute
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (U01CA138962); National Cancer Institute (R01CA138962)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2019-11-13 · J Steroid Biochem Mol Biol · vol. 198 · pág. 105522
- Editorial
- Elsevier BV
- Citado
- 159 citas · más que el 97% de estudios similares · 6.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 96 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Nutritional Studies and Diet · Antioxidant Activity and Oxidative Stress
- Palabras clave
- vitamin D supplementation, vitamin D3, omega-3 fatty acids, marine fatty acids, cancer incidence, cancer mortality, cardiovascular disease, major adverse cardiovascular events, all-cause mortality, primary prevention, older adults, African Americans, VITAL trial
- MeSH
- humans, neoplasms, cardiovascular diseases, cholecalciferol, fatty acids, omega-3, vitamins, placebo effect, aged, middle aged, female, male
3 autores
- JoAnn E. Manson🇺🇸 · autor de correspondenciaBrigham and Women's Hospital; Harvard University
- Shari S. Bassuk🇺🇸Brigham and Women's Hospital; Harvard University
- Julie E. Buring🇺🇸Brigham and Women's Hospital; Harvard University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Whether supplemental vitamin D reduces risk of cancer or cardiovascular disease (CVD) is relatively unexplored in randomized trial settings. The VITamin D and OmegA-3 TriaL (VITAL) was a nationwide, randomized, placebo-controlled, 2 × 2 factorial trial of daily vitamin D3 (2000 IU) and marine omega-3 fatty acids (1 g) in the primary prevention of cancer and CVD among 25,871 U.S. men aged ≥50 and women aged ≥55, including 5106 African Americans. Median treatment duration was 5.3 years. Vitamin D did not significantly reduce the primary endpoint of total invasive cancer incidence (hazard ratio [HR] = 0.96 [95% confidence interval 0.88-1.06]) but showed a promising signal for reduction in total cancer mortality (HR = 0.83 [0.67-1.02]), especially in analyses that accounted for latency by excluding the first year (HR = 0.79 [0.63-0.99]) or first 2 years (HR = 0.75 [0.59-0.96]) of follow-up. Vitamin D did not significantly reduce the co-primary endpoint of major CVD events (HR = 0.97 [0.85-1.12]), other cardiovascular endpoints, or all-cause mortality (HR = 0.99 [0.87-1.12]). Updated meta-analyses that include VITAL and other recent vitamin D trials indicate a significant reduction in cancer mortality but not in cancer incidence or CVD endpoints. Additional research is needed to determine which individuals may be most likely to derive a net benefit from vitamin D supplementation. (VITAL clinicaltrials.gov identifier: NCT01169259).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.